Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High‐Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis

Hideaki Tsuji; Ran Nakashima; Yuji Hosono; Yoshitaka Imura; Masato Yagita; Hajime Yoshifuji; Shintaro Hirata; Takaki Nojima; Eiji Sugiyama; Kazuhiro Hatta; Yoshio Taguchi; Masaki Katayama; Kiminobu Tanizawa; Tomohiro Handa; Ryuji Uozumi; Shuji Akizuki; Kosaku Murakami; Motomu Hashimoto; Masao Tanaka; Koichiro Ohmura; Tsuneyo Mimori

doi:10.1002/art.41105

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

A combined immunosuppressive regimen is effective for anti-MDA-5-positive DM patients with ILD. Plasmapheresis can be used for additional effect in intractable disease. Patients should be carefully monitored for opportunistic infections during treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tsuji et al. (2019) studied this question.

synapsesocial.com/papers/69d9455c00ab073a27835a47 https://doi.org/10.1002/art.41105

View Full Paper

Ask AI

Bookmark

Share

Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High‐Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis

Ask about this paper

Abstract

Discussion

Cite This Study

Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High‐Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading